Vizient Projects Drug Price Inflation at 3.81%
2024年7月30日 - 7:00PM
ビジネスワイヤ(英語)
‘Outlook’ urges health systems to prepare for
cell and gene therapy expansion
Vizient, Inc. released its summer Pharmacy Market Outlook
estimating the 2025 overall drug price inflation rate for
pharmaceuticals at 3.81% based in part on expanding indications of
previously approved medications, such as semaglutide, which
increased 77% in spend since the summer 2023 Outlook. The report
also urges providers to prepare for an increased number of
high-cost cell and gene therapies entering the market that will
significantly impact provider budgets and operational processes.
View the summer 2024 Pharmacy Market Outlook.
Currently, FDA-approved gene and cell therapies range in annual
wholesale acquisition cost (WAC) from $250,000 to $4.25 million for
a single dose. Recently approved gene therapies, ranging from $2
million to $4.25 million in WAC, include treatment indications for
inherited blood disorders such as sickle cell anemia and
beta-thalassemia and pediatric neurological conditions including
Duchenne muscular dystrophy, spinal muscular atrophy,
pre-symptomatic late-infantile and early, active cerebral
adrenoleukodystrophy. The Outlook notes that there are close to 300
cell and gene therapies currently in clinical trials across several
disease states.
“Gene and cell therapies present budgetary, operational and
revenue obstacles that require health systems’ multidisciplinary
teams and processes to quickly identify qualified patients, access
treatments and synchronize logistics for drug administration,” said
Carina Dolan, associate vice president, clinical oncology,
pharmacoeconomics and market insights, Vizient. “Providers should
be organizing cross-functionally now to prepare for these novel
therapeutics and planning a long-term approach to properly manage
them.”
In the oncology class, chimeric antigen receptor T-cell (CAR-T)
therapy, used in the treatment of blood cancers, has grown
exponentially since its first introduction to the market in 2017.
Today there are six CAR-T agents with indications for several types
of lymphoma, myeloma and now chronic lymphocytic leukemia. Five of
these products experienced a 9% WAC increase since November 2023,
and one product had a 7% price increase. All six are priced at more
than $455,000 per treatment.
In late 2023, a recent competitor to CAR-T, bispecific T-cell
engagers, surpassed CAR-T usage, according to a Vizient Clinical
Data Base analysis. Currently, there are nine approved bispecific
T-cell engager products ranging in WAC from $9,715 for weekly
treatments to $360,500 for a full treatment course. The most recent
bispecific T-cell engager approved by the FDA was for tarlatamab
(Imdelltra™, manufactured by Amgen) in May 2024, for patients with
extensive-stage small cell lung cancer.
Newly granted indications for GLP-1s, semaglutide spend up
77%
The expanding indications for GLP-1 agents, semaglutide
(Ozempic® and Wegovy®, manufactured by Novo Nordisk) and newly
launched tirzepatide (Mounjaro® and Zepbound®, manufactured by
Lilly), is becoming increasingly significant for providers as they
manage pharmacy spend. These medications not only treat diabetes
and obesity but have recently been approved by the FDA to reduce
the risk of major adverse cardiovascular events in overweight or
obese adults with established cardiovascular disease. Semaglutide,
No. 5 on the list of top medication spend among Vizient pharmacy
program participants and up 77% in spend compared to the 2023
summer Outlook, leads the list of endocrine and metabolic
medications.
“With the integration of GLP-1s into standard care protocols,
future incidence of conditions like myocardial infarction and
stroke could be altered by these chronic, lifetime management
therapy plans,” Dolan said.
The summer 2024 Pharmacy Market Outlook represents Vizient’s
best estimate of the change in the price of pharmaceuticals that
Vizient customers will purchase through the Vizient pharmacy
program between Jan. 1 and Dec. 31, 2025, based on products
purchased from April 1, 2023 through March 31, 2024.
Learn more about the Pharmacy Market Outlook.
About Vizient, Inc.
Vizient, Inc., the nation’s largest provider-driven healthcare
performance improvement company, serves more than 65% of the
nation’s acute care providers, which includes 97% of the nation’s
academic medical centers, and more than 35% of the non-acute
market. Vizient provides expertise, analytics and consulting
services, as well as a contract portfolio that represents $140
billion in annual purchasing volume. Solutions and services from
Vizient improve the delivery of high-value care by aligning cost,
quality and market performance. Headquartered in Irving, Texas,
Vizient has offices throughout the United States. Learn more at
www.vizientinc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730257419/en/
Donna Ledbetter (972) 830-6321
donna.ledbetter@vizientinc.com